Bellicum Pharmaceuticals — Investor Presentation (September 2021)
28 slides from Bellicum Pharmaceuticals's investor presentation, Sep 13, 2021
Slide 1: Building a powerful new future in cellular IO
Exhibit 99.1 Investor Presentation Building a powerful new future in cellular IO September 2021Exhibit 99.1 Investor Presentation Building a powerful new future in cellular IO September 2021
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation contains estimates, projections and other forward-looking statements, concerning, among other things: our research and development activities relating to our GoCAR™ platform, our CaspaCIDe safety switch, and related technologies; our product candidates inc
Slide 3: Building a Powerful New Future in Cellular IO
Building a Powerful New Future in Cellular IO Our GoCAR platform is engineered to break through the limitations of current cell therapies Persistence Proliferation Enhances effector cell Boosts effector cell functional persistence by proliferation and extends resisting exhaustion and survival, poten
Slide 4: Product Pipeline
Product Pipeline Establishing the clinical value of GoCAR-T in solid tumors to propel cellular IO forward Clinical Product Candidate Discovery IND-Enabling Proof-of-Concept BPX-601 Castration-Resistant Prostate Cancer PSCA GoCAR-T PSCA+ Pancreatic Cancer BPX-603 HER2+ Solid Tumors HER2 GoCAR-T (Dual
Slide 5: Technology Overview
Technology Overview 5Technology Overview 5
Slide 6: GoCAR: Differentiated Technology Platform
GoCAR: Differentiated Technology Platform Current Generation CAR Technology Next Generation GoCAR Technology Rimiducid Inducible MyD88/CD40 ”iMC” 6GoCAR: Differentiated Technology Platform Current Generation CAR Technology Next Generation GoCAR Technology Rimiducid Inducible MyD88/CD40 ”iMC” 6
Slide 7: GoCAR Proliferation: Superior Expansion and Resistance to T Cell Exhaustion
GoCAR Proliferation: Superior Expansion and Resistance to T Cell Exhaustion iMC activation limits T cell dysfunction in repeat tumor stimulation exhaustion assay T cell IL-2 production T cell expansion HER2+ tumor 100 100000 cells BPX-603 + Rim 10000 BPX-603 + Rim NT NT 1000 Repeat HER2.z HER2.z 10
Slide 8: GoCAR Persistence: Resistance to Immune Suppressive TME
GoCAR Persistence: Resistance to Immune Suppressive TME iMC overrides common inhibitory molecules in the tumor microenvironment TGF-b PD-L1 Inhibitory TME 140 35 BPX-601 + Rim BPX-601 + Rim 120 30 M2 MF 25 100 PGE MDSC 2 80 BPX-601 20 BPX-601 BPX-601 + PD-L1 BPX-601 + TGF-b 60 15 PD-L1 BPX-601 + TGF
Slide 9: CaspaCIDe Safety Switch
CaspaCIDe Safety Switch Inducible apoptosis to mitigate cell therapy-mediated adverse events Potential Applications • Controlling toxicity associated with cell therapies • Cytokine Release Syndrome • ICANS • Targeting antigens with known or potential high-risk side effects • Developing next-generati
Slide 10: Clinical Experience with CaspaCIDe (iC9)
Clinical Experience with CaspaCIDe (iC9) 1 2 Experience from Rivo-cel Program CAR-T Case Report from University of North Carolina 24 pediatric haplo-HSCT patients experienced advanced 26-year-old female with relapsed B-ALL received CD19.iC9 or steroid-refractory GvHD from iC9-containing allogeneic C
Slide 11: Dual-Switch GoCAR-T
Dual-Switch GoCAR-T A controllable system to manage CAR-T proliferation, persistence, and safety Lead Program: BPX-603 (HER2) 11Dual-Switch GoCAR-T A controllable system to manage CAR-T proliferation, persistence, and safety Lead Program: BPX-603 (HER2) 11
Slide 12: BPX-601 PSCA GoCAR-T
BPX-601 PSCA GoCAR-T 12BPX-601 PSCA GoCAR-T 12
Slide 13: BPX-601 GoCAR-T Targets Solid Tumors Expressing PSCA
BPX-601 GoCAR-T Targets Solid Tumors Expressing PSCA Product Profile Summary Unmet Need Unmet need in mCRPC remains, particularly in § Attractive first-in-class solid tumor CAR-T opportunity patients who have progressed after androgen § First-in-human experience with iMC deprivation therapy and chem
Slide 14: BPX-601: GoCAR-T Increased Immunomodulatory Cytokines
BPX-601: GoCAR-T Increased Immunomodulatory Cytokines Infusion of BPX-601 and activation with rimiducid increased immunomodulatory cytokines § Increases in Th1 and Th2 cytokines were observed with: Administration of § BPX-601 GoCAR-T cells § GoCAR-T activation with rimiducid Shaw et al, ASCO GI 2020
Slide 15: BPX-601: GoCAR-T Tumor Infiltration
BPX-601: GoCAR-T Tumor Infiltration On-treatment biopsies taken from metastatic lesions show BPX-601 tumor infiltration BPX-601 Infiltration 5 0 0 Analysis of tumor § metastases from 4 0 0 patients showed: 212 T u m o r 3 0 0 Infiltration of BPX-601 § S t r o m a GoCAR-T cells 161 A d j. N o r m a l
Slide 16: BPX-601: Modulation of Tumor Microenvironment
BPX-601: Modulation of Tumor Microenvironment Changes in gene expression consistent with productive T cell immune responses § Upregulation of T/CAR-T Differentially Expressed Genes in Tumor Metastases After BPX-601 + Rim cell associated genes (Cohort 5B, n=3) including: GZMB – Target cell killing §
Slide 17: BPX-601: BP-012 Phase 1/2 Study
BPX-601: BP-012 Phase 1/2 Study Dose escalation in relapsed metastatic castration-resistant prostate cancer (mCRPC) Planned mCRPC Phase 1 – 3+3 Design* mCRPC Dose Escalation Rationale • DL1 intended to establish safety in mCRPC at Dose Level 1 Dose Level 2 Dose Levels 3+ previously cleared dose/sche
Slide 18: Rationale for Rimiducid Dose Escalation
Rationale for Rimiducid Dose Escalation In non-clinical models, increasing exposure to rimiducid leads to… Increased Enhanced Improved GoCAR-T Cell Persistence Cytokine Production Anti-Tumor Efficacy OE19 Tumor Bioluminescence T cell Bioluminescence Serum IFN-γ Levels Day 37 post T cell transplantaK
Slide 19: BPX-603 HER-2 Dual-Switch GoCAR-T
BPX-603 HER-2 Dual-Switch GoCAR-T 19BPX-603 HER-2 Dual-Switch GoCAR-T 19
Slide 20: BPX-603 Dual Switch GoCAR-T Targeting HER2
BPX-603 Dual Switch GoCAR-T Targeting HER2 Unmet Need Product Profile Summary 5-year OS § HER2 is a validated tumor antigen expressed on numerous solid 1 + Indication Incidence HER2 1 (Stage IV) tumors with high unmet need 3 Gastric 28,000 10-30% <20% § BPX-603 designed to potentially address limita
Slide 21: Historical HER2 Studies: Modest Clinical Outcomes
Historical HER2 Studies: Modest Clinical Outcomes Study Properties Morgan, 2010 Ahmed, 2015 Feng, 2017 Ahmed, 2017 Hegde, 2019 Construct 4D5-28-BB-z FRP5-28-z Her2-BB-z FRP5-28-z FRP5-28-z Indication(s) Metastatic colon Sarcomas CCA and PCa GBM Sarcomas Patient number 1 19 11 17 10 HER2 expression ≥
Slide 22: BPX-603: Compelling Preclinical Evidence
BPX-603: Compelling Preclinical Evidence iMC co-activation enhances cell proliferation Moderate affinity scFv enhances relative to current CAR-T standards anti-tumor effect relative to low affinity FRP5 Tumor growth T cell bioluminescence 10000000 100 10 1000000 BPX-603 + Rim NT 1 FRP5 + Rim 100000
Slide 23: BPX-603 Phase 1/2 Trial Design
BPX-603 Phase 1/2 Trial Design Two-Part Safety/Activity Study of HER2-Targeted Dual Switch GoCAR-T Cells in Previously Treated HER2+ Solid Tumors Phase 1: 3+3 Dose Escalation Phase 2: Multi-Arm Dose Expansion in Select Tumor Types Cohort 1: Gastric • Expansion cohorts 10 patients each Locally advanc
Slide 24: Expanding the Use of CaspaCIDe Through Licensing
Expanding the Use of CaspaCIDe Through Licensing 24Expanding the Use of CaspaCIDe Through Licensing 24
Slide 25: Expanding the Use of CaspaCIDe Through Licensing
Expanding the Use of CaspaCIDe Through Licensing Summary New Licensing Agreements in 2021 § CaspaCIDe is the most clinically-validated safety switch, offering § The University of Texas the potential to improve the benefit/risk of cell therapies MD Anderson Cancer Center § Bellicum has established op
Slide 26: Summary
Summary 26Summary 26
Slide 27: Anticipated Key Program Goals & Milestones
Anticipated Key Program Goals & Milestones Product Candidate Goals & Milestones Planned Timing BPX-601 Initial Phase 1 data in mCRPC 1Q’22 PSCA GoCAR-T BPX-603 Initial Phase 1 data 4Q’21 HER2 GoCAR-T (Dual-Switch) 27Anticipated Key Program Goals & Milestones Product Candidate Goals & Milestones Plan
Slide 28: Investment Summary
Investment Summary Building a next generation cell therapy pipeline around the GoCAR platform GoCAR Platform Differentiated co-activation domain (MyD88/CD40) and switch technology drive greater proliferation, persistence, power, and performance BPX-601 BPX-603 • Autologous GoCAR-T targeting PSCA • A
Bellicum Pharmaceuticals — Investor Presentation (September 2021) on 6ix